News | January 13, 2010

Study Demonstrates Effectiveness of Laser Atherectomy for PAD

January 13, 2010 – A study evaluating the effectiveness of the Clir-Path laser atherectomy system met its primary endpoint by reducing the diameter of stenosis. Results from the CELLO (CLiRpath Excimer Laser System to Enlarge Lumen Openings) study were published in the December issue of the Journal of Endovascular Therapy.

CELLO evaluated the effectiveness of the FDA-cleared excimer laser ablation system with the Turbo-Booster for patients with peripheral artery disease (PAD).

On average the percent diameter stenosis was reduced from 77.3 percent to 42.5 percent immediately post Turbo-Booster use. This exceeded the goal of a 20 percent difference. Additionally, the Turbo-Booster had a low number of repeat vascular interventions, while safely improving a range of clinical and functional status assessments, researchers said

The CELLO study is a prospective, 17-center study that enrolled 65 patients with claudification, or walking impairments caused by PAD. Direct laser ablation was performed on above-the-knee arteries (in the superficial femoral and popliteal arteries) that were at least 70 percent blocked. It is common for these patients to require frequent revascularization of the target artery blockage. However, the CELLO study demonstrated 76.7 percent of patients did not require revascularization procedures one year post-treatment. Additionally, treatment demonstrated a strong safety profile, with no major adverse events through the six-month follow-up period.

Excimer laser ablation procedures are typically prescribed in combination with conventional therapies, such as balloon angioplasty and stents. While adjunctive therapies remain an important part of the PAD treatment toolkit, the CELLO trial demonstrates that the Turbo-Booster may reduce the need for stent use above the knee. For instance, only 23 percent of the study population required them. A significant proportion of the nonstent subpopulation, 74 percent, did not need revascularization within one year.

The CELLO study served as the basis for the 2007 FDA clearance of the Turbo-Booster, which offers an enhancement over prior laser ablation techniques. The Turbo-Booster assists the Turbo Elite laser catheter in delivering excimer laser energy to more of the target lesion. By rotating the laser catheter within the blood vessel, the Turbo-Booster enables ablation of more plaque than is possible with the catheter alone.

For more information: visit

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init